Payment overview · 2025
General Payments
$200.27
9 reported records · 6 companies
Healthcare provider profile · identity verified
Anjuman - Ara, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KENNER, LA · NPI 1184657314
Verified facts
What the public records show
CMS Open Payments records show Anjuman - Ara, MD received $200.27 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.93 | 31.9% | 3 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $54.50 | 27.2% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $25.25 | 12.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.28 | 11.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.67 | 9.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.64 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $200.27 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.93 | 3 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $54.50 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.95 | 2 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 247 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 55 |
| Montelukast Sodium | Montelukast Sodium | 187 | 58 |
| Losartan Potassium | Losartan Potassium | 181 | 56 |
| Metformin Hcl | Metformin Hcl | 157 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 40 |
| Gabapentin | Gabapentin | 137 | 41 |
| Lisinopril | Lisinopril | 135 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 56 |
| Allopurinol | Allopurinol | 115 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 27 |
| Omeprazole | Omeprazole | 89 | 28 |
| Carvedilol | Carvedilol | 83 | 27 |
| Alendronate Sodium | Alendronate Sodium | 74 | 26 |
| Januvia | Sitagliptin Phosphate | 66 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 24 |
| Donepezil Hcl | Donepezil Hcl | 63 | 22 |
| Meloxicam | Meloxicam | 63 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 20 |
| Irbesartan | Irbesartan | 56 | 13 |
| Ozempic | Semaglutide | 55 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 55 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 12 |
| Jardiance | Empagliflozin | 52 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 19 |
| Famotidine | Famotidine | 48 | 22 |
| Minoxidil | Minoxidil | 48 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 11 |
| Labetalol Hcl | Labetalol Hcl | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | 16 |
| Valsartan | Valsartan | 41 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | 13 |
| Simvastatin | Simvastatin | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Furosemide | Furosemide | 29 | 13 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Eliquis | Apixaban | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 15 |
| Azelastine Hcl | Azelastine Hcl | 24 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Bumetanide | Bumetanide | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.27 · 9 records | GlaxoSmithKline, LLC. | INNOVAMATRIX AC, JARDIANCE, Restrata Wound Matrix, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error